Ollin Biosciences Announces Final Data From Randomized Head-to-Head Study

Biotech firm reports results comparing its OLN324 drug to Faricimab (Vabysmo) for vision-threatening diseases.

Mar. 30, 2026 at 6:08pm

Got story updates? Submit your updates here. ›

Ollin Biosciences, a clinical-stage biotech company focused on developing therapies for vision-threatening diseases, has announced the final data from a randomized head-to-head study comparing its OLN324 drug to Faricimab (Vabysmo), a competing treatment developed by Roche.

Why it matters

The results of this study could have significant implications for the treatment of vision-threatening conditions, as it provides a direct comparison of two leading drug candidates in this space. The findings may help guide clinicians and patients in selecting the most effective therapy.

The details

The randomized study evaluated the safety and efficacy of Ollin's OLN324 drug compared to Roche's Faricimab (Vabysmo) in treating various vision-threatening diseases. Ollin reported that the study met its primary and secondary endpoints, demonstrating the potential for OLN324 to be a best-in-class therapy.

  • The study was conducted over the past 12 months.
  • Ollin announced the final data results on March 30, 2026.

The players

Ollin Biosciences, Inc.

A clinical-stage biotech company focused on developing therapies for vision-threatening diseases.

Faricimab (Vabysmo)

A competing treatment for vision-threatening diseases developed by Roche.

Got photos? Submit your photos here. ›

What’s next

Ollin plans to submit the study data to regulatory authorities for review and potential approval of OLN324 as a new treatment option.

The takeaway

This head-to-head study provides valuable data that could help guide clinicians and patients in selecting the most effective therapy for vision-threatening conditions, potentially improving patient outcomes.